Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | When is liquid biopsy needed alongside imaging to assess tumor burden?

Sabine Mouawad, MD, Gustave Roussy, Villejuif, France, comments on the role of liquid biopsy in determining tumor burden, highlighting its ability to provide molecular information, such as tumor mutations, but also noting its high cost. Her study aims to identify imaging metrics that can help determine which patients can benefit from both liquid biopsy and imaging, and which patients can rely on imaging alone, thereby reducing costs. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

To determine tumor burden, until now, imaging is still being the gold standard to evaluate it on a daily basis in routine practice. However, in the recent years, we started to see that liquid biopsy has started being implemented alongside imaging in order to determine tumor burden. What is positive about liquid biopsy is that it can give us more information. It can tell us information about the molecular aspect, which is, for example, the mutations of the tumor...

To determine tumor burden, until now, imaging is still being the gold standard to evaluate it on a daily basis in routine practice. However, in the recent years, we started to see that liquid biopsy has started being implemented alongside imaging in order to determine tumor burden. What is positive about liquid biopsy is that it can give us more information. It can tell us information about the molecular aspect, which is, for example, the mutations of the tumor. However, we know that liquid biopsy is very expensive. And what is important in our study is that we are trying to understand imaging metrics that help us say that, like, okay, this patient can benefit from both liquid biopsy and imaging. Or in this patient, in this profile, we will still use imaging and that way we can reduce the cost.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.